

**Opportunity Title:** FDA Fellowship on Comparing FDA and EMA Decisions for Complex (Hybrid) Generic Drug Applications

**Opportunity Reference Code:** FDA-CDER-2023-1253

**Organization** U.S. Food and Drug Administration (FDA)

**Reference Code** FDA-CDER-2023-1253

**How to Apply** *Connect with ORISE...on the GO!* Download the new ORISE GO mobile app in the [Apple App Store](#) or [Google Play Store](#) to help you stay engaged, connected, and informed during your ORISE experience and beyond!

A complete application consists of:

- An application
- Transcripts – Click [here](#) for detailed information about acceptable transcripts
- A current resume/CV, including academic history, employment history, relevant experiences, and publication list
- One educational or professional recommendation

All documents must be in English or include an official English translation.

If you have questions, send an email to [ORISE.FDA.CDER@oraui.org](mailto:ORISE.FDA.CDER@oraui.org). Please include the reference code for this opportunity in your email.

**Description** \*Applications will be reviewed on a rolling-basis.


The Center for Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. This research covers more than just medicines.

The project is in the Office of Generic Drugs (OGD), Immediate Office (IO). The project will aim to compare complex generic abbreviated new drug applications with regulatory outcomes at both the FDA and the European Medicines Agency (EMA) in the period of June 2017-2021. EMA assesses applications if the reference medicine was centrally authorized or if the generic medicine provides a significant innovation or advantage for patients.

Under the guidance of the mentor, the participant will gain knowledge on EMA and the FDA regulations. The participant will gain an in-depth understanding of regulations pertaining to generic drugs.


This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits


Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.




**ORISE GO**

The ORISE GO mobile app helps you stay engaged, connected and informed during your ORISE experience – from application, to offer, through your appointment and even as an ORISE alum!

Visit ORISE GO 

GET IT ON  
 **Google Play**

Download on the  
 **App Store**

**Opportunity Title:** FDA Fellowship on Comparing FDA and EMA Decisions for Complex (Hybrid) Generic Drug Applications

**Opportunity Reference Code:** FDA-CDER-2023-1253

FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:

- Non-employee nature of the ORISE appointment;
- Prohibition on ORISE Fellows performing inherently governmental functions;
- Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
- The fact that research materials and laboratory notebooks are the property of the FDA;
- ORISE fellow's obligation to protect and not to further disclose or use non-public information.

**Qualifications** The qualified candidate should have received a doctoral degree in one of the relevant fields. Degree must have been received within five years of the appointment start date.

- Eligibility Requirements**
- **Degree:** Doctoral Degree received within the last 60 month(s).
  - **Discipline(s):**
    - **Life Health and Medical Sciences** ([48](#) 👁)

**Affirmation** I have lived in the United States for at least 36 out of the past 60 months. (36 months do not have to be consecutive.)